IGA urges the public not to cut back on eye tests

Article

The International Glaucoma Association (IGA) is urging people not to cut back on eye tests due to the recession.

The International Glaucoma Association (IGA) is urging people not to cut back on eye tests due to the recession. It is estimated that the total cost of sight loss in the UK alone is £4.8 billion a year. June 8th–14th is National Glaucoma Awareness Week in the UK and a campaign is urging everyone over the age of 40 to have a sight test at least once every two years.

David Wright, chief executive officer of the IGA commented: "A comprehensive eye test for glaucoma including all three glaucoma tests is painless and quick and amazingly good value for money when compared with the consequences of losing your vision.

"Let us not come out of this recession, whenever that may be, with a recession legacy of blind and partially sighted people who had 'nothing wrong with their sight' when they decided not to have their eyes tested."

Doctors can obtain free posters and leaflets by calling +44 1233 648170 or email info@iga.org.uk

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.